Oruka Therapeutics, Inc.
Oruka Therapeutics, Inc.
MENLO PARK, CA
Loading...
Price History
Market Data
| Market Cap | 3.19B |
| P/E Ratio | - |
| P/B Ratio | 6.76 |
| EPS | - |
| Dividend Yield | - |
| D/E Ratio | 0.04 |
| Current Ratio | 22.37 |
| Currency | USD |
Key Financial Metrics
-
Revenue
-105.43M
Net Income
-
EPS (Diluted)
-153.36M
Free Cash Flow
Profitability
Gross Margin
-
Operating Margin
-
Net Profit Margin
-
EBITDA
-122.05M
Returns & Efficiency
Return on Assets (ROA)
-21.6%
Return on Equity (ROE)
-22.3%
Dividend Yield
-
EPS
-
Financial Health
Total Assets
488.62M
Total Debt
-
Debt to Equity
0.04x
Current Ratio
22.37
Insider Trading
Last 12 months
0
Buys
0
Sells
0
Insiders
Quick Access Filings
10-K
Annual Report
Loading...
10-Q
Quarterly Report
Loading...
8-K
Recent News
Loading...
Company Data Library
Earnings Transcripts
Loading...
Press Releases
Loading...
Filing Sections
Loading...
Company Info
| Industry | Chemicals & Allied Products |
| HQ | MENLO PARK, CA |
| Fiscal Year | 2025 |
Peers
LILLY ELI & CO
LLY
915.80B
P/E: --
ELI LILLY & CO
LLY
915.80B
P/E: --
534.79B
P/E: --
ABBVIE INC.
ABBV
357.89B
P/E: --
BEIGENE, LTD.
BEIGF
306.50B
P/E: 632.4
BEONE MEDICINES LTD.
BEIGF
306.50B
P/E: 632.4
276.35B
P/E: --
MERCK & CO. INC.
MRK
276.35B
P/E: --
Quick Links
Financial Statistics
Valuation
Market Cap$3.19B
P/E Ratio (TTM)-
Price to Book6.76
EV/Revenue-
EV/EBITDA-
Profitability
Gross Margin-
Operating Margin-
Net Margin-
ROE-22.3%
ROA-21.6%
Leverage & Liquidity
Debt to Equity0.04
Current Ratio22.37
Total Debt-
Total Assets$488.62M
Stockholders' Equity$471.93M
Income Statement (FY 2025)
Revenue-
Gross Profit-
Operating Income$-122.05M
Net Income$-105.43M
EPS (Diluted)-
Cash Flow (FY 2025)
Free Cash Flow$-153.36M
Cash & Equivalents$46.94M
Revenue Growth-
SEC Filings by Category
Insider Trading Activity
Neutral
0 Buys $0
0 Sales $0
0 Exercises $0
Net: $0
| Insider | Title | Date | Type | Shares | Price | Value |
|---|
Company Information
| Business Address | 855 OAK GROVE AVE. SUITE 100 MENLO PARK, CA 94025 |
| Phone | N/A |
| Incorporated | DE, US |
| EIN | 363855489 |
| Fiscal Year End | 1231 |
| Shares Outstanding | 49.54M |
| Stockholders' Equity | $471.93M |
| Cash & Equivalents | $46.94M |
Recent Filings
View All
SCHEDULE 13D/A
Amended Schedule 13D
Amendment to Schedule 13D
Filed: 2026-05-04
Local
8-K
Current Report
Report of material events (acquisitions, earnings, executive changes)
Filed: 2026-04-30
Local
424B5
Prospectus Supplement
Prospectus supplement filed under Rule 424(b)(5)
Filed: 2026-04-29
Local
424B5
Prospectus Supplement
Prospectus supplement filed under Rule 424(b)(5)
Filed: 2026-04-27
Local
424B5
Prospectus Supplement
Prospectus supplement filed under Rule 424(b)(5)
Filed: 2026-04-27
Local
8-K
Current Report
Report of material events (acquisitions, earnings, executive changes)
Filed: 2026-04-27
Local
424B7
Prospectus (Rule 424b7)
Prospectus filed under Rule 424(b)(7)
Filed: 2026-04-21
Local
144
Proposed Sale Notice
Notice of proposed sale of securities
Filed: 2026-04-15
Local
4
Insider Transaction Report
Statement of changes in beneficial ownership
Filed: 2026-04-15
Local
4
Insider Transaction Report
Statement of changes in beneficial ownership
Filed: 2026-03-17
Local
4
Insider Transaction Report
Statement of changes in beneficial ownership
Filed: 2026-03-17
Local
4
Insider Transaction Report
Statement of changes in beneficial ownership
Filed: 2026-03-17
Local
4
Insider Transaction Report
Statement of changes in beneficial ownership
Filed: 2026-03-17
Local
4
Insider Transaction Report
Statement of changes in beneficial ownership
Filed: 2026-03-17
Local
10-K
Annual Report
Comprehensive annual financial report with audited statements
Filed: 2026-03-12
Local
Loading...
Loading management data...
Loading...
Loading board of directors...
Loading...
Loading institutional holders...
Loading...
Loading short interest data...
Financial Charts Annual (10-K)
Interactive financial visualizations
Show:
Revenue & Income Trends
Revenue & Profit
Profit Margins
Balance Sheet Breakdown
Assets Composition
Capital Structure
Cash Flow Analysis
Cash Flow Components
Free Cash Flow
Growth & Performance
Revenue Growth Rate (YoY %)
Key Ratio Trends
Company Profile
General Information
| Company Name | Oruka Therapeutics, Inc. |
| Ticker | ORKA |
| Exchange | -- |
| Sector | Manufacturing |
| Industry | Chemicals & Allied Products |
| Headquarters | MENLO PARK, CA |
| Fiscal Year | 2025 |
Financial Summary
| Market Cap | 3.19B |
| Revenue | - |
| Net Income | -105.43M |
| P/E Ratio | - |
| EPS | - |
| Net Margin | - |
| ROE | -22.3% |
| Dividend Yield | - |
Insider Transactions
Loading...
My Notes & Files
Personal Notes
Attached Files
Loading...